T2EVOLVE

The ambition of the EU project T2EVOLVE is to ignite the transformation of engineered T-cell therapy into an accessible, scalable, reliable, and socioeconomically desirable treatment modality in cancer medicine. The interdisciplinary T2EVOLVE consortium is made up of 27 European partners from 9 nations and is being coordinated by Universitätsklinikum Würzburg, Germany, and Servier, France. Partners include university and non-university research facilities, pharmaceutical, and biotechnology companies, as well as regulatory authorities. Funding This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875171.